Xeris Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Xeris Pharmaceuticals's estimated annual revenue is currently $35.3M per year.
- Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
- Xeris Pharmaceuticals's estimated revenue per employee is $90,358
- Xeris Pharmaceuticals's total funding is $155M.
- Xeris Pharmaceuticals's current valuation is $275M. (January 2022)
Employee Data
- Xeris Pharmaceuticals has 391 Employees.
- Xeris Pharmaceuticals grew their employee count by 147% last year.
Xeris Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | General Counsel, VP | Reveal Email/Phone |
2 | VP CMC/QC | Reveal Email/Phone |
3 | VP Product Development and CMC-R&D | Reveal Email/Phone |
4 | VP, Market Access, Pricing & Reimbursement | Reveal Email/Phone |
5 | SVP, Investor Relations & Corporate Communications | Reveal Email/Phone |
6 | SVP, Quality and Chief Compliance and Risk Officer | Reveal Email/Phone |
7 | VP, Medical Communications & Regional Medical Affairs | Reveal Email/Phone |
8 | Chief Financial Officer | Reveal Email/Phone |
9 | Director, Process Development and Manufacturing | Reveal Email/Phone |
10 | Associate Director, Document and Clinical Systems Management | Reveal Email/Phone |
Xeris Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.1M | 65 | 30% | N/A | N/A |
#2 | $75.6M | 376 | 7% | N/A | N/A |
#3 | $23.9M | 119 | 13% | $35M | N/A |
#4 | $12.7M | 63 | -3% | N/A | N/A |
#5 | $5.4M | 27 | -25% | N/A | N/A |
#6 | $6M | 30 | -35% | N/A | N/A |
#7 | $6.6M | 33 | -8% | N/A | N/A |
#8 | $13.5M | 67 | -3% | N/A | N/A |
#9 | $186.3M | 927 | 19% | N/A | N/A |
#10 | $4.4M | 22 | -4% | N/A | N/A |
What Is Xeris Pharmaceuticals?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system
keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power
$155M
Total Funding
391
Number of Employees
$35.3M
Revenue (est)
147%
Employee Growth %
$275M
Valuation
N/A
Accelerator
Xeris Pharmaceuticals News
XERIS PHARMACEUTICALS, INC. TO ACQUIRE STRONGBRIDGE BIOPHARMA PLC IN STOCK AND CVR TRANSACTION, CREATING AN INNOVATIVE LEADER IN ENDOCRINOLOGY AND RARE DISEASES Transaction Creates Fast-Growing Biopharmaceutical Company with Two Commercial Assets and Robust Clinical Pipeline with Multiple Near- ...
Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...
After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...
So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).
Xeris Pharmaceuticals, founded in 2005 in Austin, filed on Thursday with the Securities and Exchange Commission to go public on the Nasdaq Stock Exchange with an initial public offering valued at $75 million. The company, now based in Chicago, has strong ties to the Austin startup community. X ...
Other Companies in Chicago
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $172.5M | 391 | 22% | N/A |
#2 | $88M | 391 | 24% | N/A |
#3 | $70.9M | 391 | 7% | N/A |
#4 | $48.9M | 391 | 4% | N/A |
#5 | $142.1M | 392 | 12% | N/A |
Xeris Pharmaceuticals Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2011-12-13 | $1.5M | A | Central Texas Angel Network | Article |
| 2013-07-15 | $2.3M | Undisclosed | Multiple | Article |
| 2015-01-09 | $17.9M | Undisclosed | Article | |
| 2016-01-08 | $41.0M | C | Redmile Group | Article |
| 2017-05-19 | $30.0M | C | Redmile Group | Article |
| 2018-03-09 | $45.0M | Undisclosed | Silicon Valley Bank | Article |
| 2018-03-09 | $10.0M | C | Merieux Développement | Article |